Lymphocyte radiosensitivity is a significant prognostic factor for morbidity in carcinoma of the cervix.
Authors
West, Catharine M LDavidson, Susan E
Elyan, S A
Valentine, Helen R
Roberts, Stephen A
Swindell, Ric
Hunter, Robin D
Affiliation
CRC Experimental Radiation Oncology Group, Paterson Institute for Cancer Research, Manchester, United Kingdom. cwest@picr.man.ac.ukIssue Date
2001-09-01
Metadata
Show full item recordAbstract
PURPOSE: To study the relationship between pretreatment peripheral blood lymphocyte radiosensitivity and morbidity following radiation therapy. METHODS AND MATERIALS: A prospective study was carried out in which patients with carcinoma of the cervix underwent radiation therapy. Intrinsic radiosensitivity was measured on pretreatment peripheral blood lymphocytes, using a limiting dilution clonogenic assay. Late morbidity was assessed using the Franco-Italian glossary. Results were correlated in an actuarial analysis. RESULTS: There were no correlations between the measured lymphocyte radiosensitivity (SF2) and colony-forming efficiency, patient age, tumor grade, or disease stage. For 83 patients, lymphocyte SF2 was a significant prognostic factor for the probability of developing both any (p = 0.002) and Grade 3 (p = 0.026) morbidity. In 174 patients, stage showed borderline significance as a prognostic factor for morbidity (p = 0.056). However, the type of treatment (intracavitary alone, intracavitary plus parametrial irradiation, single insertion plus whole-pelvis irradiation) was significantly associated with the probability of developing late complications (p = 0.013). There was a weak significant inverse correlation between lymphocyte SF2 and grade of morbidity (r = -0.34, p = 0.002). CONCLUSION: These data highlight the importance of normal cell radiosensitivity as a factor determining radiation therapy response. They also show that peripheral blood lymphocyte SF2 is a highly significant prognostic factor for the probability of developing late radiation morbidity, and that carcinoma of the cervix is a good model for testing radiobiologic principles in the clinic.Citation
Lymphocyte radiosensitivity is a significant prognostic factor for morbidity in carcinoma of the cervix. 2001, 51 (1):10-5 Int. J. Radiat. Oncol. Biol. Phys.Journal
International Journal of Radiation Oncology, Biology, PhysicsPubMed ID
11516845Type
ArticleLanguage
enISSN
0360-3016Related articles
- The intrinsic radiosensitivity of normal and tumour cells.
- Authors: West CM, Davidson SE, Elyan SA, Swindell R, Roberts SA, Orton CJ, Coyle CA, Valentine H, Wilks DP, Hunter RD, Hendry JH
- Issue date: 1998 Apr
- Pretreatment plasma TGF beta 1 levels are prognostic for survival but not morbidity following radiation therapy of carcinoma of the cervix.
- Authors: Dickson J, Davidson SE, Hunter RD, West CM
- Issue date: 2000 Nov 1
- An audit of the treatment of carcinoma of the uterine cervix using external beam radiotherapy and a single line source brachytherapy technique.
- Authors: Tan LT, Jones B, Gee A, Kingston RE
- Issue date: 1997 Dec
- Carcinoma of the uterine cervix. II. Lack of impact of prolongation of overall treatment time on morbidity of radiation therapy.
- Authors: Perez CA, Grigsby PW, Castro-Vita H, Lockett MA
- Issue date: 1996 Jan 1
- Potential application of the ATP cell viability assay in the measurement of intrinsic radiosensitivity in cervical cancer.
- Authors: Tam KF, Ng TY, Liu SS, Tsang PC, Kwong PW, Ngan HY
- Issue date: 2005 Mar